Physician profile
Mitul Patel
NPI 1770080350
$4,573.89
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.12 · 2021: $668 · 2022: $1,535 · 2023: $2,051 · 2024: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $668.29 | 2021-2023 | |
| Novo Nordisk INC | $426.19 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $358.77 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $275.92 | 2021-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.20 | 2021-2024 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $205.00 | 2021-2024 | Farxiga, Fasenra |
| Amgen INC. | $199.85 | 2021-2024 | Otezla, Repatha, Evenity |
| Pfizer INC. | $192.69 | 2023-2024 | |
| Glaxosmithkline, LLC. | $184.29 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Corium, LLC | $181.60 | 2022-2023 | Azstarys |
| Amarin Pharma, INC. | $167.12 | 2021-2022 | |
| Mylan Specialty L.P. | $160.26 | 2021-2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $148.23 | 2022-2023 | |
| Abbott Laboratories | $138.87 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $107.95 | 2021-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.